Advertisement

Intensive Care Medicine

, Volume 36, Issue 1, pp 123–130 | Cite as

Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock

  • Jennifer M. KaplanEmail author
  • Alvin Denenberg
  • Marie Monaco
  • Marchele Nowell
  • Hector Wong
  • Basilia Zingarelli
Pediatric Original

Abstract

Purpose

To assess changes in peroxisome proliferator-activated receptor-γ (PPARγ) in peripheral blood mononuclear cells (PBMC) from critically ill children with sepsis. Additionally, to investigate the effects of sepsis on the endogenous activator of PPARγ, 15-deoxy-∆12,14-PGJ2 (15d-PGJ2), and the downstream targets of PPARγ activity, adiponectin and resistin.

Methods

Single-center, prospective case–control study in critically ill children with systemic inflammatory response syndrome, sepsis or septic shock.

Results

PPARγ nuclear protein expression was decreased but PPARγ activity was increased in PBMC from children with septic shock compared with controls. PPARγ activity on day 1 was significantly higher in patients with higher pediatric risk of mortality (PRISM) score compared with controls [mean 0.22 optical density (OD) ± standard error of the mean (SEM) 0.03 versus 0.12 OD ± 0.02; p < 0.001]. Patients with resolved sepsis had increased levels of the endogenous PPARγ ligand, 15d-PGJ2, compared with patients with systemic inflammatory response syndrome (SIRS) and septic shock (77.7 ± 21.7 versus 58 ± 16.5 pg/ml; p = 0.03). Plasma high-molecular-weight adiponectin (HMWA) and resistin levels were increased in patients with septic shock on day 1 and were significantly higher in patients with higher PRISM scores. Nonsurvivors from sepsis had higher resistin levels on the first day of hospitalization compared with survivors from septic shock [660 ng/ml, interquartile range (IQR) 585–833 ng/ml versus 143 ng/ml, IQR 66–342 ng/ml; p < 0.05].

Conclusions

Sepsis is associated with altered PPARγ expression and activity in PBMC. Plasma adipokines correlate with risk of mortality scores in sepsis and may be useful biomarkers. Further studies are needed to understand the mechanisms underlying changes in PPARγ in sepsis.

Keywords

Sepsis Resistin Adiponectin 15-Deoxy-∆12,14-PGJ2 PPARγ Cytokines 

Notes

Acknowledgments

We would like to thank the parents who enrolled their children into this study during an emotionally difficult time. Supported, in part, by grants K12 HD028827 (J.M.K.), T32 ES10957 (J.M.K.), R01 GM067202 (B.Z.), and R01 GM064619 (H.W.) from the NIH, Bethesda, MD, and by the Translational Research Initiative at Cincinnati Children’s Hospital Medical Center (J.M.K.).

Supplementary material

134_2009_1654_MOESM1_ESM.doc (32 kb)
Supplementary material 1 (DOC 32 kb)

References

  1. 1.
    Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79–82CrossRefPubMedGoogle Scholar
  2. 2.
    Jiang C, Ting AT, Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82–86CrossRefPubMedGoogle Scholar
  3. 3.
    Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813–819CrossRefPubMedGoogle Scholar
  4. 4.
    Palmer CN, Hsu MH, Griffin HJ, Johnson EF (1995) Novel sequence determinants in peroxisome proliferator signaling. J Biol Chem 270:16114–16121CrossRefPubMedGoogle Scholar
  5. 5.
    Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK (2000) 15-deoxy-delta 12, 14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97:4844–4849CrossRefPubMedGoogle Scholar
  6. 6.
    Kaplan J, Cook JA, O’Connor M, Zingarelli B (2007) Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12, 14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells. Shock 28:722–726PubMedGoogle Scholar
  7. 7.
    Zingarelli B, Sheehan M, Hake PW, O’Connor M, Denenberg A, Cook JA (2003) Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12, 14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 171:6827–6837PubMedGoogle Scholar
  8. 8.
    Kaplan JM, Cook JA, Hake PW, O’Connor M, Burroughs TJ, Zingarelli B (2005) 15-deoxy-delta12, 14-prostaglandin J2 (15D-PGJ2), a peroxisome proliferator activated receptor gamma ligand, reduces tissue leukosequestration and mortality in endotoxic shock. Shock 24:59–65CrossRefPubMedGoogle Scholar
  9. 9.
    Haraguchi G, Kosuge H, Maejima Y, Suzuki J, Imai T, Yoshida M, Isobe M (2008) Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 34:1304–1312CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou M, Wu R, Dong W, Simms HH, Wang P (2004) Hepatic peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is downregulated in sepsis. Shock 21:39Google Scholar
  11. 11.
    Culver DA, Barna BP, Raychaudhuri B, Bonfield TL, Abraham S, Malur A, Farver CF, Kavuru MS, Thomassen MJ (2004) Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 30:1–5CrossRefPubMedGoogle Scholar
  12. 12.
    Han X, Osuntokun B, Benight N, Loesch K, Frank SJ, Denson LA (2006) Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn’s disease and murine colitis. Am J Pathol 169:1999–2013CrossRefPubMedGoogle Scholar
  13. 13.
    Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka MT (2005) Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol 175:4948–4955PubMedGoogle Scholar
  14. 14.
    van den Akker EL, Koper JW, Joosten K, de Jong FH, Hazelzet JA, Lamberts SW, Hokken-Koelega AC (2009) Glucocorticoid receptor mRNA levels are selectively decreased in neutrophils of children with sepsis. Intensive Care Med 35:1247–1254CrossRefPubMedGoogle Scholar
  15. 15.
    Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW, Standiford TJ (2008) Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-{gamma}. Blood 112:4250–4258CrossRefPubMedGoogle Scholar
  16. 16.
    Soller M, Tautenhahn A, Brune B, Zacharowski K, John S, Link H, von Knethen A (2006) Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis. J Leukoc Biol 79:235–243CrossRefPubMedGoogle Scholar
  17. 17.
    Goldstein B, Giroir B, Randolph A (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6:2–8CrossRefPubMedGoogle Scholar
  18. 18.
    Pollack MM, Ruttimann UE, Getson PR (1988) Pediatric risk of mortality (PRISM) score. Crit Care Med 16:1110–1116PubMedCrossRefGoogle Scholar
  19. 19.
    Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152–12162CrossRefPubMedGoogle Scholar
  20. 20.
    Zhou M, Wu R, Dong W, Jacob A, Wang P (2008) Endotoxin downregulates peroxisome proliferator-activated receptor-gamma via the increase in TNF-alpha release. Am J Physiol Regul Integr Comp Physiol 294:R84–R92PubMedGoogle Scholar
  21. 21.
    Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC (2000) Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. J Biol Chem 275:1241–1246CrossRefPubMedGoogle Scholar
  22. 22.
    Camp HS, Tafuri SR (1997) Regulation of peroxisome proliferator-activated receptor gamma activity by mitogen-activated protein kinase. J Biol Chem 272:10811–10816CrossRefPubMedGoogle Scholar
  23. 23.
    Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK (1997) Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128–5132CrossRefPubMedGoogle Scholar
  24. 24.
    Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM (2000) Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 275:18527–18533CrossRefPubMedGoogle Scholar
  25. 25.
    Shan ZZ, Masuko-Hongo K, Dai SM, Nakamura H, Kato T, Nishioka K (2004) A potential role of 15-deoxy-delta(12, 14)-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis. J Biol Chem 279:37939–37950CrossRefPubMedGoogle Scholar
  26. 26.
    Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5:698–701CrossRefPubMedGoogle Scholar
  27. 27.
    Shibata T, Kondo M, Osawa T, Shibata N, Kobayashi M, Uchida K (2002) 15-deoxy-delta 12, 14-prostaglandin J2. A prostaglandin D2 metabolite generated during inflammatory processes. J Biol Chem 277:10459–10466CrossRefPubMedGoogle Scholar
  28. 28.
    Sunden-Cullberg J, Nystrom T, Lee ML, Mullins GE, Tokics L, Andersson J, Norrby-Teglund A, Treutiger CJ (2007) Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med 35:1536–1542CrossRefPubMedGoogle Scholar
  29. 29.
    Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419CrossRefPubMedGoogle Scholar
  30. 30.
    Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174:5789–5795PubMedGoogle Scholar
  31. 31.
    Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL (2002) Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 530:158–162CrossRefPubMedGoogle Scholar
  32. 32.
    Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651–25653CrossRefPubMedGoogle Scholar
  33. 33.
    Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655–1663CrossRefPubMedGoogle Scholar
  34. 34.
    Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–2099CrossRefPubMedGoogle Scholar
  35. 35.
    Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O’Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998–1007CrossRefPubMedGoogle Scholar
  36. 36.
    Teoh H, Quan A, Bang KW, Wang G, Lovren F, Vu V, Haitsma JJ, Szmitko PE, Al-Omran M, Wang CH, Gupta M, Peterson MD, Zhang H, Chan L, Freedman J, Sweeney G, Verma S (2008) Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 295:E658–E664CrossRefPubMedGoogle Scholar
  37. 37.
    Uji Y, Yamamoto H, Tsuchihashi H, Maeda K, Funahashi T, Shimomura I, Shimizu T, Endo Y, Tani T (2009) Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality. Surgery 145:550–557CrossRefPubMedGoogle Scholar
  38. 38.
    Keller P, Moller K, Krabbe KS, Pedersen BK (2003) Circulating adiponectin levels during human endotoxaemia. Clin Exp Immunol 134:107–110CrossRefPubMedGoogle Scholar
  39. 39.
    Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, Tabita-Martinez J, Sellers KF, Rickels MR, Ahima RS, Reilly MP (2007) Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab 92:2272–2279CrossRefPubMedGoogle Scholar
  40. 40.
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406–3410CrossRefPubMedGoogle Scholar

Copyright information

© Copyright jointly hold by Springer and ESICM 2009

Authors and Affiliations

  • Jennifer M. Kaplan
    • 1
    Email author
  • Alvin Denenberg
    • 1
  • Marie Monaco
    • 1
  • Marchele Nowell
    • 1
  • Hector Wong
    • 1
  • Basilia Zingarelli
    • 1
  1. 1.Cincinnati Children’s Hospital Medical CenterThe University of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations